Kugler A R, Olson S C, Smith D E
Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, MI, USA.
J Chromatogr B Biomed Appl. 1995 Apr 21;666(2):360-7. doi: 10.1016/0378-4347(94)00588-v.
Quinapril and quinaprilat concentrations were determined in perfusate, urine, and perfusate ultrafiltrate using a specific and sensitive reversed-phase high-performance liquid chromatographic procedure with radiochemical detection, coupled to liquid scintillation counting spectrometry. Quinapril and quinaprilat were measured in perfusate and urine after pretreatment with acetonitrile and subsequent centrifugation. Perfusate ultrafiltrate was used as collected. Two quinapril diketopiperazine metabolites, PD 109488 and PD 113413, were separated chromatographically from quinapril, quinaprilat, and from each other. Assay performance for quinapril and quinaprilat was assessed by examining precision and accuracy of the assay over four days. Using a 100-microliters sample volume, the limit of quantitation for both 3H-quinapril and 3H-quinaprilat (sp. act. approximately 2.0 muCi/micrograms) was 1 ng/ml.
采用具有放射化学检测功能的特异性灵敏反相高效液相色谱法并结合液体闪烁计数光谱法,测定灌注液、尿液及灌注液超滤液中的喹那普利和喹那普利拉浓度。用乙腈预处理并随后离心后,测定灌注液和尿液中的喹那普利和喹那普利拉。收集的灌注液超滤液直接使用。两种喹那普利二酮哌嗪代谢物,即PD 109488和PD 113413,通过色谱法与喹那普利、喹那普利拉以及彼此分离。通过在四天内检查该测定法的精密度和准确度来评估喹那普利和喹那普利拉的测定性能。使用100微升的样品体积,3H-喹那普利和3H-喹那普利拉(比活度约为2.0μCi/μg)的定量限均为1 ng/ml。